ArticleExperimental and therapeutic medicine2020
MicroRNA-1307-3p accelerates the progression of colorectal cancer via regulation of TUSC5.
Article in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Pooled it
- MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.Molecular medicine (Cambridge, Mass.) · 2022Review
- miR-1307 promotes hepatocarcinogenesis by CALR-OSTC-endoplasmic reticulum protein folding pathway.iScience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to explore the roles of microRNA-1307-3p (miR-1307-3p) in colorectal cancer (CRC). Firstly, the expression level of miR-1307-3p in CRC cells was measured using reverse transcription-quantitative PCR. Subsequently, Cell Counting Kit-8 and Transwell invasion assays were performed to evaluate the effects of miR-1307-3p on CRC cell proliferation and invasion, respectively. Bioinformatics tools and dual luciferase reporter assays were used to validate the targets of miR-1307-3p. Rescue experiments were performed to confirm tumor suppressor candidate 5 (TUSC5) as a functional target of miR-1307-3p. miR-1307-3p levels were revealed to be upregulated in CRC cells when compared with the normal human epithelial cell line. Knockdown of miR-1307-3p inhibited CRC cell growth and invasiveness. Bioinformatics analysis and dual-luciferase activity reporter assays demonstrated that miR-1307-3p binds the 3'-untranslated region of TUSC5. Finally, rescue experiments validated that miR-1307-3p was able to regulate CRC cell behaviors via regulating TUSC5 expression. Together, the current results indicate that miR-1307-3p functions as an oncogenic miRNA via targeting TUSC5 in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.